Molecular characterization of deletional forms of beta-thalassemia in Taiwan

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 期刊論文 > Item 310903500/30351

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30351

题名:	Molecular characterization of deletional forms of beta-thalassemia in Taiwan
作者:	Peng, CT;Liu, SC;Chiou, SS;Kuo, PL;Shih, MC;Chang, JY;Chang, JG
贡献者:	附設醫院檢驗醫學部;China Med Coll Hosp, Dept Lab Med, Taichung, Taiwan;China Med Coll Hosp, Dept Pediat, Taichung, Taiwan;Kaohsiung Med Univ, Dept Pediat, Kaohsiung, Taiwan;Natl Cheng Kung Univ, Sch Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan
日期:	2003
上传时间:	2010-09-24 14:53:48 (UTC+8)
出版者:	SPRINGER-VERLAG
摘要:	Background: It was reported that multidrug resistance gene 1 (MDR1) encoding human P-glycoprotein (Pgp) may play an important role in multidrug resistance of lung cancer. Therefore, before initiating chemotherapy, it is important to accurately determine the presence of Pgp in lung cancer, to achieve a satisfactory chemotherapy response. Objectives: The aim of this study was to compare immunohistochemical analyses of Pgp expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 50 patients with stage IIIb or IV NSCLC were enrolled in this study. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the 3rd month after completion of treatment by clinical and radiological methods. Results: All of the 28 (100%) cases with good response had negative Pgp expression and 15 of the 22 (68%) cases with poor response had positive Pgp expression (p < 0.05). No significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between good response and poor response groups. Conclusions: Although Pgp expression in NSCLC does not fully predict chemotherapy response to paclitaxel-based therapy, detection of Pgp expression will aid in planning paclitaxel-based therapy for patients with advanced NSCLC. Further studies with a larger number of patients and a longer time of follow-up are necessary to confirm our findings. Copyright (C) 2003 S. Karger AG, Basel.
關聯:	ANNALS OF HEMATOLOGY 82(1):33-36
显示于类别:	[台中附設醫院] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....